On September 2, Novo-Nordisk A/S rose 3.08% in regular trading, trading at $46.65/share, with turnover of $57.96 million. The rally was primarily driven by the confirmation that China's National Medical Products Administration has officially accepted the company's marketing application for oral semaglutide tablets for long-term weight management.

The oral formulation has already demonstrated strong commercial traction in the U.S., accumulating over 5 million prescriptions since its January launch and generating $855 million in sales in the first half alone. Clinical data show that the 25mg dose achieves an average weight reduction of 16.6% over 64 weeks, comparable to the injectable version. China's adult overweight and obese population stands at approximately 540 to 560 million, while GLP-1 weight-loss drug penetration remains at only around 2.5%, suggesting significant market potential.

Additionally, Novo-Nordisk A/S has initiated the OASIS 5 clinical study enrolling 450 participants to evaluate lower-dose oral semaglutide, aiming to expand its addressable patient base. The broader pharmaceutical sector traded positively, with Johnson & Johnson up 3.25% and Eli Lilly up 2.03%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)